Haitao Chen

Dr. Haitao Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FZFan Zhang
Fan Zhang
YZYanlin Zhou
Yanlin Zhou
HCHaitao Chen
Haitao Chen
HJHao Jiang
Hao Jiang
FZFeini Zhou
Feini Zhou
MXMaosheng Xu
Maosheng Xu
The anxiety and depression caused by inflammatory bowel diseases (IBD) are known to greatly affect the mental health of patients. The mechanism of psychiatric disorders caused by IBD is not fully understood. Previous research has suggested that the gut microbiome plays a key role in IBD. Curcumin is a yellow polyphenol extracted from the rhizome of the ginger plant, which has been shown to have effects against both depression and anxiety. Research has indicated that curcumin affects the gut microbiome and exerts antianxiety and neuroprotective effects through the microbiota‐gut‐brain axis (MGB). However, whether curcumin can alleviate the psychiatric disorders caused by IBD and how curcumin affects the MGB axis through the gut microbiota have not been fully understood. Therefore, this study was aimed at determining the metabolic parameters and microbiological environment in the peripheral and central nervous system to determine the effects of curcumin against anxiety induced by dextran sulfate sodium salt (DSS) in mice. To elaborate on the link between the gut microbiota and how curcumin alleviates anxiety‐like behaviors, we performed a fecal microbiota transplantation (FMT) experiment. The results suggested that curcumin can effectively relieve anxiety‐like behaviors caused by DSS in mice. Further, curcumin treatment can alleviate disturbances in the gut microbiota and systemic disorders of lipid metabolism caused by DSS. Finally, through FMT, we verified that curcumin increased phosphatidylcholine in the prefrontal cortex of the mice and alleviated DSS‐induced anxiety‐like behaviors by modulating specific gut microbiota. We also revealed that Muribaculaceae may be a key part of the gut microbiota for curcumin to alleviate DSS‐induced anxiety‐like behaviors through the MGB axis.

31 May 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CYChenxiao Ye
Chenxiao Ye
CWChanghong Wu
Changhong Wu
YLYan Li
Yan Li
CCChao Chen
Chao Chen
XLXinrong Li
Xinrong Li
YGYong Guo
Yong Guo

14 July 2024 in Heliyon
Verified
Journal Article
Open access
CWChanghong Wu
Changhong Wu
JYJie Yang
Jie Yang
CYChenxiao Ye
Chenxiao Ye
HWHui Wu
Hui Wu
WSWenxi Shu
Wenxi Shu
QYQinghua Yao
Qinghua Yao
5-Fluorouracil (5-Fu), a prominent chemotherapeutic agent for colorectal cancer (CRC) treatment, is often associated with gastrointestinal toxicities, particularly diarrhea. Our previous study demonstrated that berberine (BBR) ameliorates 5-Fu-induced intestinal mucosal injury by modulating the gut microbiota in rats. Nevertheless, the precise molecular mechanism underlying BBR's protective effect on intestinal mucosa remains elusive, and its impact on the anti-tumor efficacy of 5-Fu warrants further investigation. The effect of BBR on 5-Fu-induced intestinal mucosal injury was investigated using a tumor-bearing murine model, employing H&E staining, 16 S rDNA sequencing, transcriptome sequencing, Western blot analysis, cell experiments and constructing a pseudo-germ-free tumor xenograft model. Our findings demonstrate that BBR alleviates intestinal mucosal damage, reduces the levels of inflammatory factors (IL-6, TNF-α, and IL-1β), and inhibits epithelial cell apoptosis in 5-Fu-treated mice without compromising 5-Fu's anti-tumor efficacy. Moreover, 16 S rDNA sequencing indicated that BBR significantly increases the abundance of Akkermansia and decreases the abundance of pathogenic bacteria Escherichia/Shigella at the genus level. Mechanistically, transcriptome sequencing and Western blot analysis confirmed that BBR upregulates PI3K/AKT/mTOR expression in the intestinal mucosa. However, this effect was not observed in tumor tissues. Notably, BBR did not demonstrate a direct protective effect on 5-Fu-treated CCD841 and SW480 cells. Additionally, BBR had no effect on the PI3K/AKT/mTOR pathway in the intestinal tissue of the 5-Fu-treated mouse model with a depleted gut microbiota. This study indicates that BBR alleviates 5-Fu-induced intestinal mucosal injury by modulating the gut microbiota and regulating the PI3K/AKT/mTOR signaling pathway without compromising the anti-tumor efficacy of 5-Fu.

19 January 2023 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
HJHao Jiang
Hao Jiang
RLRongrong Li
Rongrong Li
FZFan Zhang
Fan Zhang
FZFeini Zhou
Feini Zhou
JLJiangnan Lin
Jiangnan Lin
MXMaosheng Xu
Maosheng Xu
Visceral pain caused by inflammatory bowel disease (IBD) greatly diminishes the quality of life in affected patients. Yet, the mechanism of how IBD causes visceral pain is currently not fully understood. Previous studies have suggested that the central nervous system (CNS) and gut-brain axis (GBA) play an important role in IBD-inducing visceral pain. As one of the treatments for IBD, electroacupuncture (EA) has been used to treat various types of pain and gastrointestinal diseases in clinical practice. However, whether EA relieves the visceral pain of IBD through the gut-brain axis has not been confirmed. To verify the relationship between visceral pain and CNS, the following experiments were conducted. 1H-NMR analysis was performed on the prefrontal cortex (PFC) tissue obtained from IBD rat models to determine the link between the metabolites and their role in EA treatment against visceral pain. Western blot assay was employed for detecting the contents of glutamate transporter excitatory amino acid transporters 2 (EAAT2) and the glutamate receptor N-methyl-D-aspartate (NMDA) to verify whether EA treatment can alleviate neurotoxic symptoms induced by abnormal increases of glutamate. Study results showed that the glutamate content was significantly increased in the PFC of TNBS-induced IBD rats. This change was reversed after EA treatment. This process was associated with increased EAAT2 expression and decreased expression of NMDA receptors in the PFC. In addition, an increase in intestinal glutamic-metabolizing bacteria was observed. In conclusion, this study suggests that EA treatment can relieve visceral pain by reducing glutamine toxicity in the PFC, and serves an alternative clinical utility.

17 January 2026 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
SHShengyang Hu
Shengyang Hu
YXYaxuan Xu
Yaxuan Xu
JCJiongli Chen
Jiongli Chen
LZLingyu Zhang
Lingyu Zhang
HCHaitao Chen
Haitao Chen
RLRongrong Li
Rongrong Li
Chemotherapy-induced diarrhea (CID) is a common complication among colorectal cancer patients receiving chemotherapeutic treatment. This condition adversel

13 August 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YLYulin Li
Yulin Li
LZLingyu Zhang
Lingyu Zhang
HTHan Tong
Han Tong
ZXZhixiang Xu
Zhixiang Xu
YWYanghong Wei
Yanghong Wei
HCHaitao Chen
Haitao Chen
Introduction: Postoperative recurrence and metastasis of colorectal cancer (CRC) are critical factors affecting long-term survival, and how to prevent postoperative recurrence and metastasis remains an urgent clinical challenge. Studies indicate that berberine has a preventive effect against colorectal adenoma recurrence; however, no research has yet investigated its preventive efficacy against CRC. This trial aims to evaluate the clinical efficacy and safety of BBR in preventing postoperative recurrence and metastasis of CRC by comparing it with a placebo group. Methods and analysis: This trial is a multicenter, randomized, controlled, double-blind clinical study. A total of 306 eligible patients with stage IIIB, IIIC CRC who had undergone surgery will be randomly assigned in a 1:1 ratio to the placebo group and the trial group. The primary outcome is 2-year disease-free survival (DFS) rate, while secondary outcomes include 1-year and 2-year postoperative recurrence rates of CRC, as well as the incidence of adverse reactions. We expect that this randomized controlled trial (RCT) will provide high-quality evidence on BBR for the prevention of postoperative recurrence of CRC, which can achieve more significant clinical benefits to patients with stage IIIB, IIIC CRC. Ethics and dissemination: This study has been approved by the institutional review board of The Second Affiliated Hospital of Zhejiang Chinese Medical University (No. 2025-246-IH01). Clinical trial registration: www.chictr.org.cn , identifier: ChiCTR2600117441.